PULMATRIX, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
PULMATRIX, INC. (PULM) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $1.30 million for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-09-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-09-17
- PULMATRIX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.00M, a 54.55% decline from fiscal 2023.
- PULMATRIX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $4.40M, a 21.43% decline from fiscal 2022.
- PULMATRIX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $5.60M, a 285.14% increase from fiscal 2021.
- PULMATRIX, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $1.45M, a 2.42% decline from fiscal 2020.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.30M S-4/A · filed 2026-09-17 | |
| 2024-12-31 | $2.00M 10-K · filed 2025-03-21 | |
| 2023-12-31 | $4.40M 10-K · filed 2024-03-28 | |
| 2022-12-31 | $5.60M 10-K · filed 2023-03-30 | |
| 2021-12-31 | $1.45M 10-K · filed 2022-03-29 | |
| 2020-12-31 | $1.49M 10-K · filed 2021-03-23 | |
| 2019-12-31 | $33.17M 10-K · filed 2020-03-26 | |
| 2018-12-31 | $5.80M 10-K · filed 2019-02-19 | |
| 2017-12-31 | $17.60M 10-K · filed 2019-02-19 | -$11.06M 10-K · filed 2018-03-13 |
| 2015-03-31 | $2.06M 10-K · filed 2015-06-10 | |
| 2014-03-31 | $1.21M 10-K · filed 2015-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |